Insulet PODD Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total Revenue by Product | |||||
| Drug Delivery | $34.1M-12.3% | $38.9M+8.1% | $36M-37.4% | $57.5M-34.2% | |
| International | $754.3M+44.1% | $523.4M+27.6% | $410.1M+13.0% | $363M+0.9% | |
| Total Omnipod products | $2.67B+31.6% | $2.03B+22.4% | $1.66B+33.1% | $1.25B+23.4% | |
| U.S.Omnipod | $1.92B+27.2% | $1.51B+20.6% | $1.25B+41.4% | $884.8M+35.8% | |
| Property, plant and equipment, net by Geography | |||||
| Malaysia | $702.9M— | —— | —— | —— | |
| Other | $182M— | —— | —— | —— | |
| U.S. | $1.87B— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Insulet break its business down?
- Insulet (PODD) reports total revenue by product across 4 parts — Drug Delivery, International, Total Omnipod products and U.S.Omnipod. Each is extracted from the segment footnotes and tracked over time.
- Where does Insulet's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Insulet's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
